Prediction of pre‐eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy‐associated plasma protein‐A, free β‐human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation

Kevin Spencer, C. K. H. Yu, Makrina Savvidou, Aris T. Papageorghiou, K. H. NicolaidesUltrasound 2006 · DOI

TL;DR

This study explores a more accurate method for predicting pre-eclampsia, a serious pregnancy complication. By combining traditional ultrasound measurements of uterine artery blood flow with new blood tests for specific pregnancy hormones (activin A and inhibin A), researchers significantly improved the ability to identify pregnancies at risk. This enhanced screening could lead to earlier interventions and better outcomes for mothers and babies.

What Problem Does This Paper Address?

Pre-eclampsia is a dangerous condition during pregnancy characterized by high blood pressure and potential organ damage. Early detection is crucial for managing the condition and preventing severe complications. Current screening methods, like measuring uterine artery blood flow resistance using Doppler ultrasound around 20-25 weeks of gestation, can identify about 45% of pregnancies that will develop pre-eclampsia with a 5% false positive rate. However, this leaves a significant portion of at-risk pregnancies undetected. The paper aims to improve this detection rate by investigating whether combining Doppler ultrasound with maternal serum levels of specific biochemical markers (pregnancy-associated plasma protein-A (PAPP-A), free beta-human chorionic gonadotropin (β-hCG), activin A, and inhibin A) can provide a more sensitive and specific screening tool.

Methods

The researchers conducted a case-control study. They collected blood samples and performed transvaginal color flow Doppler measurements of uterine artery pulsatility index (PI) on pregnant women between 22 and 24 weeks + 6 days gestation. They then identified a group of women who subsequently developed pre-eclampsia (24 cases) and a control group with normal outcomes (144 women). Maternal serum levels of PAPP-A, free β-hCG, activin A, and inhibin A were measured.

Statistical analysis involved:

  • Regression analysis: To understand the relationships between the biochemical markers themselves and between these markers and the uterine artery mean PI.
  • Multivariate Gaussian modeling: To create a combined model incorporating uterine artery mean PI and the biochemical markers.
  • Receiver-Operating Characteristic (ROC) curve analysis: To evaluate the performance of individual markers and the combined model in discriminating between cases and controls, determining detection rates at specific false positive rates.

Datasets

The study utilized data from a screening study for pre-eclampsia. The dataset comprised:

  • 24 singleton pregnancies that subsequently developed pre-eclampsia.
  • 144 singleton pregnancies with normal outcomes, matched for gestation and sample storage duration.

This dataset was used for evaluating the predictive performance of various screening methods.

Key Insights and Ideas

  • Synergistic Prediction: The most significant insight is that combining uterine artery Doppler velocimetry with maternal serum levels of activin A and inhibin A dramatically improves the prediction of pre-eclampsia compared to using either method alone. This suggests these markers are not just independently predictive but work together to signal an increased risk.
  • Hormonal Clues: The study highlights that elevated levels of activin A and inhibin A in maternal serum during the second trimester are associated with a higher risk of developing pre-eclampsia. This points to potential underlying placental dysfunction or altered hormonal signaling pathways.
  • Second Trimester Timing is Key: The research confirms that screening for pre-eclampsia can be effectively performed in the second trimester (22-24 weeks), providing a window for intervention before the condition becomes severe.
  • PAPP-A and β-hCG Less Predictive Alone: While PAPP-A and free β-hCG are known markers for other pregnancy complications (like chromosomal abnormalities), they showed lower predictive power for pre-eclampsia in this specific second-trimester screening context compared to activin A and inhibin A.

Key Results

  • Individual Marker Performance: At a 5% false positive rate (FPR), uterine artery mean PI alone detected 50% of pre-eclampsia cases. Activin A detected 44%, inhibin A detected 35%, free β-hCG detected 10%, and PAPP-A detected 5%.
  • Combined Model Performance:
    • Combining uterine artery mean PI with maternal serum activin A and inhibin A achieved a detection rate of 75% at a 5% FPR.
  • This combination further improved to 92% detection rate at a 10% FPR.
  • Uterine Artery PI Elevated: The uterine artery mean PI was significantly higher in the pre-eclampsia group (1.70) compared to the controls (0.908).
  • Biochemical Markers Elevated: Maternal serum levels of PAPP-A, free β-hCG, activin A, and inhibin A were also significantly higher in the pre-eclampsia group.

Limitations and Future Work

  • Sample Size: While the study achieved a good number of controls, the number of pre-eclampsia cases (n=24) is relatively small, which can limit the generalizability of findings, especially for subgroup analyses.
  • Severe Pre-eclampsia Analysis: The analysis for severe pre-eclampsia (delivery before 35 weeks) was limited due to insufficient numbers, preventing a full ROC analysis for this critical subgroup.
  • Future Work: The authors suggest that further research could explore the use of these combined markers in larger, prospective studies to validate their findings and refine the screening model. Investigating the specific biological mechanisms behind the elevated hormone levels in pre-eclamptic pregnancies would also be valuable. The paper implies that this combined approach could be integrated into routine antenatal care.

Summary updated

Abstract

Screening for pre-eclampsia by uterine artery PI at 22 + 0 to 24 + 6 weeks' gestation can be improved by measurement of activin A and inhibin A levels.
BibTeX
@inproceedings{spencer2006prediction,
  author = {Kevin Spencer and C. K. H. Yu and Makrina Savvidou and Aris T. Papageorghiou and K. H. Nicolaides},
  title = {{Prediction of pre‐eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy‐associated plasma protein‐A, free β‐human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation}},
  booktitle = {Ultrasound},
  year = {2006},
  doi = {10.1002/uog.2676},
}
Figure